Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Siltuximab (Primary)
- Indications Amyloid light-chain amyloidosis; Multiple myeloma
- Focus Therapeutic Use
- 14 Mar 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 14 Mar 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 19 Dec 2017 Status changed from not yet recruiting to recruiting.